{"id":"nalirifox-plus-targeted-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4297595","moleculeType":"Small molecule","molecularWeight":"515.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nal-IRI is a liposomal formulation of irinotecan that stabilizes topoisomerase I-DNA complexes, leading to DNA damage and cell death. When combined with 5-FU (which inhibits thymidylate synthase and incorporates into DNA/RNA) and targeted therapy agents, this combination aims to improve efficacy in difficult-to-treat cancers. The targeted therapy component is designed to address specific molecular drivers in the tumor.","oneSentence":"NALIRIFOX is a combination of nal-IRI (irinotecan liposomal) and 5-fluorouracil that inhibits topoisomerase I and nucleotide synthesis, combined with targeted therapy to enhance anti-tumor activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:32.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer or other solid tumors (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT07309289","phase":"PHASE3","title":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NALIRIFOX plus targeted therapy","genericName":"NALIRIFOX plus targeted therapy","companyName":"Shanghai Zhongshan Hospital","companyId":"shanghai-zhongshan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NALIRIFOX is a combination of nal-IRI (irinotecan liposomal) and 5-fluorouracil that inhibits topoisomerase I and nucleotide synthesis, combined with targeted therapy to enhance anti-tumor activity. Used for Metastatic pancreatic cancer or other solid tumors (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}